HighFDA (Drugs)·D-0321-2025·2025-04-16
[pending] LACOSAMIDE (LACOSAMIDE)
Pending LLM rewrite. Source: FDA_DRUG D-0321-2025.
- Product
- LACOSAMIDE — LACOSAMIDE (LACOSAMIDE)
- Category
- Drug
- Distribution
- Distributed nationwide
Recalls
All US Product Recalls
Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.
How to read this listing
Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means deaths or serious injuries are reported, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.
The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.
Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.
Filters
Minimum severity
1026–1050 of 5047
- HighFDA (Drugs)·D-0312-2025·2025-04-16
[pending] GABAPENTIN (GABAPENTIN)
Pending LLM rewrite. Source: FDA_DRUG D-0312-2025.
- Product
- GABAPENTIN — GABAPENTIN (GABAPENTIN)
- Category
- Drug
- Distribution
- Distributed nationwide
- HighFDA (Drugs)·D-0336-2025·2025-04-16
[pending] CARVEDILOL (CARVEDILOL)
Pending LLM rewrite. Source: FDA_DRUG D-0336-2025.
- Product
- CARVEDILOL — CARVEDILOL (CARVEDILOL)
- Category
- Drug
- Distribution
- Distributed nationwide
- HighFDA (Drugs)·D-0324-2025·2025-04-16
[pending] NITROGLYCERIN (NITROGLYCERIN)
Pending LLM rewrite. Source: FDA_DRUG D-0324-2025.
- Product
- NITROGLYCERIN — NITROGLYCERIN (NITROGLYCERIN)
- Category
- Drug
- Distribution
- Distributed nationwide
- HighFDA (Drugs)·D-0325-2025·2025-04-16
[pending] PRAVASTATIN SODIUM (PRAVASTATIN SODIUM)
Pending LLM rewrite. Source: FDA_DRUG D-0325-2025.
- Product
- PRAVASTATIN SODIUM — PRAVASTATIN SODIUM (PRAVASTATIN SODIUM)
- Category
- Drug
- Distribution
- Distributed nationwide
- HighFDA (Drugs)·D-0326-2025·2025-04-16
[pending] FLUPHENAZINE HYDROCHLORIDE (FLUPHENAZINE HYDROCHLORIDE)
Pending LLM rewrite. Source: FDA_DRUG D-0326-2025.
- Product
- FLUPHENAZINE HYDROCHLORIDE — FLUPHENAZINE HYDROCHLORIDE (FLUPHENAZINE HYDROCHLORIDE)
- Category
- Drug
- Distribution
- Distributed nationwide
- HighFDA (Drugs)·D-0310-2025·2025-04-16
[pending] VENLAFAXINE (VENLAFAXINE)
Pending LLM rewrite. Source: FDA_DRUG D-0310-2025.
- Product
- VENLAFAXINE — VENLAFAXINE (VENLAFAXINE)
- Category
- Drug
- Distribution
- Distributed nationwide
- HighFDA (Drugs)·D-0337-2025·2025-04-16
[pending] LACOSAMIDE (LACOSAMIDE)
Pending LLM rewrite. Source: FDA_DRUG D-0337-2025.
- Product
- LACOSAMIDE — LACOSAMIDE (LACOSAMIDE)
- Category
- Drug
- Distribution
- Distributed nationwide
- HighFDA (Drugs)·D-0361-2025·2025-04-16
[pending] CHLORPROMAZINE HYDROCHLORIDE (CHLORPROMAZINE HYDROCHLORIDE)
Pending LLM rewrite. Source: FDA_DRUG D-0361-2025.
- Product
- CHLORPROMAZINE HYDROCHLORIDE — CHLORPROMAZINE HYDROCHLORIDE (CHLORPROMAZINE HYDROCHLORIDE)
- Category
- Drug
- Distribution
- Distributed nationwide
- HighFDA (Drugs)·D-0320-2025·2025-04-16
[pending] GABAPENTIN (GABAPENTIN)
Pending LLM rewrite. Source: FDA_DRUG D-0320-2025.
- Product
- GABAPENTIN — GABAPENTIN (GABAPENTIN)
- Category
- Drug
- Distribution
- Distributed nationwide
- HighFDA (Drugs)·D-0314-2025·2025-04-16
[pending] FENOFIBRATE (FENOFIBRATE)
Pending LLM rewrite. Source: FDA_DRUG D-0314-2025.
- Product
- FENOFIBRATE — FENOFIBRATE (FENOFIBRATE)
- Category
- Drug
- Distribution
- Distributed nationwide
- HighFDA (Drugs)·D-0341-2025·2025-04-16
[pending] PRAVASTATIN SODIUM (PRAVASTATIN SODIUM)
Pending LLM rewrite. Source: FDA_DRUG D-0341-2025.
- Product
- PRAVASTATIN SODIUM — PRAVASTATIN SODIUM (PRAVASTATIN SODIUM)
- Category
- Drug
- Distribution
- Distributed nationwide
- HighFDA (Drugs)·D-0330-2025·2025-04-16
[pending] LACOSAMIDE (LACOSAMIDE)
Pending LLM rewrite. Source: FDA_DRUG D-0330-2025.
- Product
- LACOSAMIDE — LACOSAMIDE (LACOSAMIDE)
- Category
- Drug
- Distribution
- Distributed nationwide
- HighFDA (Drugs)·D-0360-2025·2025-04-16
[pending] Proactiv Skin Smoothing Exfoliator (Benzoyl Peroxide 2.5%), Packaged as a) 6 fl. oz. (177.4 mL), UPC
Pending LLM rewrite. Source: FDA_DRUG D-0360-2025.
- Product
- Proactiv Skin Smoothing Exfoliator (Benzoyl Peroxide 2.5%), Packaged as a) 6 fl. oz. (177.4 mL), UPC 7 35786 01528 2; b) 0.33 OZ (9.45g), UPC 8 42944 10223 1; Distributed by Alchemee, LLC, Santa Monica, CA 90401,
- Category
- Drug
- Distribution
- Distributed nationwide
- HighFDA (Drugs)·D-0343-2025·2025-04-16
FDA Recalls Lacosamide Tablets for Manufacturing Quality Deviations
Glenmark Pharmaceuticals is recalling Lacosamide 150mg tablets nationwide due to manufacturing quality deviations. Consumers should contact their pharmacy or healthcare provider regarding their supply.
- Product
- LACOSAMIDE — LACOSAMIDE (LACOSAMIDE)
- Category
- Drug
- Distribution
- Distributed nationwide
- HighFDA (Drugs)·D-0333-2025·2025-04-16
[pending] SOLIFENACIN SUCCINATE (SOLIFENACIN SUCCINATE)
Pending LLM rewrite. Source: FDA_DRUG D-0333-2025.
- Product
- SOLIFENACIN SUCCINATE — SOLIFENACIN SUCCINATE (SOLIFENACIN SUCCINATE)
- Category
- Drug
- Distribution
- Distributed nationwide
- ModerateFDA (Drugs)·D-0348-2025·2025-04-16
Cetirizine HCL tablets recalled for manufacturing process deviations
Glenmark Pharmaceuticals is voluntarily recalling Cetirizine HCL 10mg tablets distributed nationwide. The recall was initiated due to Current Good Manufacturing Practice deviations.
- Product
- CETIRIZINE HCL — CETIRIZINE HCL (CETIRIZINE)
- Category
- Drug
- Distribution
- Distributed nationwide
- ModerateFDA (Drugs)·D-0318-2025·2025-04-16
Prescription Voriconazole Antifungal Tablets Recalled Nationwide for Manufacturing Deviations
Glenmark Pharmaceuticals is voluntarily recalling Voriconazole tablets nationwide due to manufacturing process deviations. No illnesses or injuries have been reported.
- Product
- VORICONAZOLE — VORICONAZOLE (VORICONAZOLE)
- Category
- Drug
- Distribution
- Distributed nationwide
- ModerateFDA (Drugs)·D-0313-2025·2025-04-16
Sofosbuvir and Velpatasvir Tablets Recalled for Defective Blister Pack Sealing
Asegua Therapeutics is recalling 18,541 cartons of Sofosbuvir and Velpatasvir tablets nationwide due to defective blister packs that are not properly sealed, resulting in loose tablets in cartons. No illnesses or injuries have been reported.
- Product
- SOFOSBUVIR AND VELPATASVIR — SOFOSBUVIR AND VELPATASVIR (VELPATASVIR AND SOFOSBUVIR)
- Category
- Drug
- Distribution
- Distributed nationwide
- ModerateFDA (Drugs)·D-0317-2025·2025-04-16
Solifenacin succinate tablets recalled nationwide for manufacturing practice deviations
Glenmark Pharmaceuticals is recalling solifenacin succinate 10mg tablets nationwide due to manufacturing process deviations. The voluntary recall affects specific lot numbers distributed across the United States.
- Product
- SOLIFENACIN SUCCINATE — SOLIFENACIN SUCCINATE (SOLIFENACIN SUCCINATE)
- Category
- Drug
- Distribution
- Distributed nationwide
- ModerateFDA (Drugs)·D-0345-2025·2025-04-16
FDA Recalls Saxagliptin Tablets Due to Manufacturing Deviations
Glenmark Pharmaceuticals is recalling Saxagliptin 2.5mg tablets nationwide due to manufacturing quality issues. The firm initiated this voluntary recall on March 13, 2025.
- Product
- SAXAGLIPTIN — SAXAGLIPTIN (SAXAGLIPTIN)
- Category
- Drug
- Distribution
- Distributed nationwide
- ModerateFDA (Drugs)·D-0323-2025·2025-04-16
Glenmark Rufinamide Tablets Recalled for Manufacturing Process Deviations
Glenmark Pharmaceuticals is recalling Rufinamide 200mg tablets nationwide due to manufacturing process deviations. The voluntary recall affects certain lot numbers with July 2025 expiration dates.
- Product
- RUFINAMIDE — RUFINAMIDE (RUFINAMIDE)
- Category
- Drug
- Distribution
- Distributed nationwide
- ModerateFDA (Drugs)·D-0350-2025·2025-04-16
Pravastatin Sodium Tablets Recalled Due to Manufacturing Practice Deviations
Glenmark Pharmaceuticals is voluntarily recalling Pravastatin Sodium 80mg tablets due to Current Good Manufacturing Practice deviations. The nationwide recall affects specific lot numbers and remains ongoing.
- Product
- PRAVASTATIN SODIUM — PRAVASTATIN SODIUM (PRAVASTATIN SODIUM)
- Category
- Drug
- Distribution
- Distributed nationwide
- ModerateFDA (Drugs)·D-0335-2025·2025-04-16
Drug Recall: Ranolazine Extended-Release Tablets Due to Manufacturing Deviations
Glenmark Pharmaceuticals is recalling Ranolazine Extended-Release 1000mg tablets (Lot 17240040) nationwide due to manufacturing deviations. This is a voluntary, firm-initiated recall.
- Product
- RANOLAZINE — RANOLAZINE (RANOLAZINE)
- Category
- Drug
- Distribution
- Distributed nationwide
- ModerateFDA (Drugs)·D-0329-2025·2025-04-16
Glenmark Pharmaceuticals Recalls Indomethacin Capsules for Manufacturing Deviations
Glenmark Pharmaceuticals is voluntarily recalling Indomethacin Extended-Release Capsules (75mg) distributed nationwide due to Good Manufacturing Practice deviations identified during FDA oversight.
- Product
- INDOMETHACIN — INDOMETHACIN (INDOMETHACIN)
- Category
- Drug
- Distribution
- Distributed nationwide